A 45-year-old female Asian non-smoker with stage IA poorly-differentiated lung adenocarcinoma (pT1aN0M0) harboring an EGFR del-19 mutation underwent left lower lobectomy and postoperative adjuvant chemotherapy in March 2016...NGS and immunostaining indicated an EGFR del-19 mutation and a strong positive expression of PD-L1 (TPS = 60%). Then she received aumolertinib (110 mg daily) as the first-line treatment in April 2020...To the best of our knowledge, this is the longest PFS for these patients and the first of aumolertinib in the treatment of NSCLC patients with both EGFR mutation and high PD-L1 expression, which provides supporting data for the use of aumolertinib in these patients.